NEW CANAAN, CT, November 4, 2003—The Sabin Vaccine Institute, a non-profit research and education organization based in New Canaan, today concluded the second meeting of the Cancer Vaccine Consortium (CVC). The three-day meeting was held in Bethesda, Maryland and drew attendees from the United States, Canada and Europe. The purpose of the CVC is to enhance collaboration among companies undertaking research and development on cancer immunotherapies. The goal is to speed the time it will take to make cancer vaccines available among the range of therapies for cancer patients.

Several presentations were provided on the subject of regulatory affairs, including one by Kathryn Zoon, PhD, deputy director of the National Cancer Institute, and former chief of the U.S. Food & Drug Administrations Center for Biologics Research and Evaluation. It focused on the regulatory framework for cancer vaccines, including the drug and biologic development cycle. According to Dr. Zoon, approximately 200 immunotherapies for cancer are under development and 19 of those are in the Phase III, or efficacy clinical trials.

A number of presentations regarding intellectual property generated strong interest among participants, including those by Michael Whitham, Esq., a Virginia-based attorney specializing in intellectual property law with Whitham, Curtis & Christofferson, P.C. and his associate Robert N. Cook, P.C. of the same firm. Whitham addressed patents in the consortium setting, while Cook outlined patent pools and antitrust.

The meeting was attended by members of the Sabin Vaccine Institute’s New Canaan offices, including Chairman H.R. Shepherd, DSc, and CVC executive director Nathan Tinker, PhD. “This was a very good meeting,” remarked Shepherd, and he proposed that the group meet at least twice a year to keep the strong momentum that has developed to date.

For more information about the Cancer Vaccine Consortium, visit www.sabin.orgor contact Nathan Tinker, [email protected], 203-972-7907.

The mission of the Albert B. Sabin Vaccine Institute is to save lives by stimulating development of new vaccines and increasing immunization rates throughout the world.

EDITOR’s NOTE: A scanned photograph of accompanies this release and is in jpg format. See captions on following page.